Complete remission with tyrosine kinase inhibitors in renal cell carcinoma

Journal of Clinical Oncology

Volumn 30, Issue 5, 2012, Pages 482-487

  Albiges, Laurence ^a   Oudard, Steṕhane ^b   Negrier, Sylvie ^c   Caty, Armelle ^d   Gravis, Gwenaed̈lle ^e   Joly, Florence ^f   Duclos, Brigitte ^g   Geoffrois, Lionel ^h   Rolland, Fred́eŕic ⁱ   Guillot, Aline ^j   Laguerre, Brigitte ^k   Legouffe, Eric ^l   Kohser, Fred́eŕic ^m   Dietrich, Pierre Yves ^o   Theodore, Christine A ⁿ   Escudier, Bernard ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c UNIVERSITÉ DE LYON   (France)

^d CENTRE OSCAR LAMBRET   (France)

^e INSTITUT PAOLI CALMETTES   (France)

^f CHU CÔTE DE NACRE   (France)

^g UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^h CENTRE ALEXIS VAUTRIN   (France)

ⁱ CENTRE RENÉ GAUDUCHEAU   (France)

^j Institut de Cancerologie de la Loire   (France)

^k CENTRE EUGÈNE MARQUIS   (France)

^l Institut de Cancerologie du Gard   (France)

^m Pasteur Hospital   (France)

ⁿ FOCH HOSPITAL   (France)

^o GENEVA UNIVERSITY HOSPITALS   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB;

ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CONTROLLED STUDY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; FEASIBILITY STUDIES; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MEDICAL RECORDS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEPHRECTOMY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIDINES; PYRROLES; QUESTIONNAIRES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84856939964     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.2516     Document Type: Article

References (31)

1. Coppin C, Porzsolt F, Awa A, et al: Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 1:CD001425, 2005
2. Fisher RI, Rosenberg SA, Fyfe G: Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 6:S55-S57, 2000 (suppl 1)
3. Fyfe G, Fisher RI, Rosenberg SA, et al: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688- 696, 1995
4. McDermott DF, Regan MM, Clark JI, et al: Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23:133-141, 2005 (Pubitemid 41702632)
5. Ljungberg B, Cowan N, Hanbury DC, et al: Guidelines on renal cell carcinoma. http://www.uroweb.org/?id=218&gid=4
6. Escudier B, Kataja V: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v137-v139, 2010 (suppl 5)
7. Motzer RJ, Hutson TE, Tomczak P, et al: Overall survival and updated results for sunitinib versus interferon alfa in first-line treatment of patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584-3590, 2009
8. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007 (Pubitemid 46089673)
9. Sternberg CN, Davis ID, Mardiak J, et al: Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 28:1061-1068, 2010
10. Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281, 2007 (Pubitemid 46849157)
11. Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456, 2008
12. Escudier B, Bellmunt J, Negrier S, et al: Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival. J Clin Oncol 28:2144-2150, 2010
13. Rini BI, Halabi S, Rosenberg JE, et al: Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206. J Clin Oncol 28:2137-2143, 2010
14. Heng DY, Rini BI, Garcia J, et al: Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma. Clin Genitourin Cancer 5:446-451, 2007 (Pubitemid 351219698)
15. García-Campelo R, Quindos M, Vazquez DD, et al: Renal cell carcinoma: Complete pathological response in a patient with gastric metastasis of renal cell carcinoma. Anticancer Drugs 21:S13-S15, 2010 (suppl 1)
16. Calvo OF, Vazquez DD, Lopez MR, et al: Renal cell carcinoma: Complete response. Anticancer Drugs 21:S17-S18, 2010 (suppl 1)
17. Négrier S, Escudier B, Gomez F, et al: Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: A report from the Groupe Francais d'Immunotherapie. Ann Oncol 13:1460-1468, 2002
18. Gore ME, Szczylik C, Porta C, et al: Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: An expanded-access trial. Lancet Oncol 10: 757-763, 2009
19. Staehler M, Haseke N, Zilinberg E, et al: Complete remission achieved with angiogenic therapy in metastatic renal cell carcinoma including surgical intervention. Urol Oncol 28:139-144, 2010
20. Rini BI, Shaw V, Rosenberg JE, et al: Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases. Clin Genitourin Cancer 5:232-234, 2006 (Pubitemid 46190386)
21. Johannsen M, Staehler M, Ohlmann CH, et al: Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy. Ann Oncol 22:657-663, 2011
22. Mancuso MR, Davis R, Norberg SM, et al: Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116:2610-2621, 2006 (Pubitemid 44511625)
23. Harrison M, Jeraj R, Vanderhoek M: Characterization of proliferative rebound during drug holiday by FLT-PET imaging in patients treated with sunitinib (SU). J Clin Oncol 28:256s, 2010 (suppl; abstr 3094)
24. Jeraj R, Liu G, Simoncic U: Concurrent assessment of vasculature and proliferative pharmacodynamics in patients treated with VEGFR TKI. J Clin Oncol 28:245s, 2010 (suppl; abstr 3050)
25. Ebos JM, Lee CR, Kerbel RS: Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 15:5020-5025, 2009
26. Loges S, Mazzone M, Hohensinner P, et al: Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited. Cancer Cell 15:167-170, 2009
27. Ravaud A: How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents. Ann Oncol 20:i7-i12, 2009 (suppl 1)
28. Schmidinger M, Arnold D, Szczylik C, et al: Optimising the use of sunitinib in metastatic renal cell carcinoma: An update from clinical practice. Cancer Invest 28:856-864, 2010
29. Rini BI, Atkins MB: Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 10: 992-1000, 2009
30. Ravaud A: Maintenance therapy after CR: CON. Presented at the 5th European International Kidney Cancer Symposium, London, United Kingdom, May 7-8, 2010
31. Sadeghi S, Albiges L, Wood LS, et al: Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: Feasibility and clinical outcome. Cancer [epub ahead of print on December 2, 2011]